Dyne Therapeutics, Inc., a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscul...
Amgen announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA® (inebilizumab-cdon) in adults ...
AbbVie announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE® (mirvetuximab s...
Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with E...
The Series C financing was led by a global strategic investor along with participation from new investors Aphelion Cardeation and Unorthodox Ventures. Ex...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “D...
-SK pharmteco, a global pharmaceutical subcontract development and manufacturing organization, CDMO), has just reached an important step in its sustainab...
Company successfully meets key milestone with design lock that integrates and finalizes enhancements to its licensed Apex 6 Radiofrequency (“RF&rdq...
Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development...
Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to treating cardiometabolic diseases driven by obesity, announced the pub...
UCB, a global biopharmaceutical company, announced that Epilepsia published findings from the final analysis of the long-term open-label extension (OLE) st...
GC Cell, under the leadership of CEO Sungyong Won, announced the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5...
Centivax, a biotechnology company that develops broad-spectrum vaccines to combat rapidly evolving pathogens, has announced a strategic collaboration with ...
Gilead Sciences, Inc. presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company...
© 2025 Biopharma Boardroom. All Rights Reserved.
